“…TNT1/2 antibodies also robustly label tau inclusions in several non-AD tauopathies including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease, and chronic traumatic encephalopathy (CTE; Kanaan et al, 2011Kanaan et al, , 2012Combs et al, 2016;Cox et al, 2016;Tiernan et al, 2016;Combs and Kanaan, 2017). Moreover, pathological forms of tau known to inhibit FAT including oligomers, AT8 phospho-tau, and tau phosphorylated at Ser422 are all recognized by TNT1 and TNT2 antibodies in the context of human tauopathies (Kanaan et al, 2011(Kanaan et al, , 2012(Kanaan et al, , 2016Patterson et al, 2011;Combs et al, 2016;Cox et al, 2016;Tiernan et al, 2016;Morris et al, 2020). Overall, this body of work strongly supports a mechanism linking several specific pathological tau species to aberrant PAD exposure, abnormal activation of a PP1-GSKβ pathway, and deficits in FAT.…”